EP2596366A4 - Kombinationstherapie mit mdm2 und efgr-hemmern - Google Patents

Kombinationstherapie mit mdm2 und efgr-hemmern

Info

Publication number
EP2596366A4
EP2596366A4 EP11810417.3A EP11810417A EP2596366A4 EP 2596366 A4 EP2596366 A4 EP 2596366A4 EP 11810417 A EP11810417 A EP 11810417A EP 2596366 A4 EP2596366 A4 EP 2596366A4
Authority
EP
European Patent Office
Prior art keywords
mdm2
combination therapy
efgr
inhibitors
efgr inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11810417.3A
Other languages
English (en)
French (fr)
Other versions
EP2596366A1 (de
Inventor
Benjamin Mugrage
Ignatius Turchi
Matthew Sills
Jane Ong
John Allocco
Pam Wines
Margarita Bastos
Joseph P Errico
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ERRICO, JOSEPH P.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/020418 external-priority patent/WO2011085129A2/en
Application filed by Individual filed Critical Individual
Publication of EP2596366A1 publication Critical patent/EP2596366A1/de
Publication of EP2596366A4 publication Critical patent/EP2596366A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11810417.3A 2010-07-21 2011-07-21 Kombinationstherapie mit mdm2 und efgr-hemmern Withdrawn EP2596366A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36648010P 2010-07-21 2010-07-21
PCT/US2011/020418 WO2011085129A2 (en) 2010-01-06 2011-01-06 Methods and compositions of targeted drug development
PCT/US2011/020414 WO2011085126A2 (en) 2010-01-06 2011-01-06 Methods and compositions of targeted drug development
US12/986,146 US8618302B2 (en) 2010-01-06 2011-01-06 Methods and compositions of targeted drug development
PCT/US2011/044882 WO2012012653A1 (en) 2010-07-21 2011-07-21 Combination therapy with mdm2 and efgr inhibitors

Publications (2)

Publication Number Publication Date
EP2596366A1 EP2596366A1 (de) 2013-05-29
EP2596366A4 true EP2596366A4 (de) 2014-04-16

Family

ID=45497182

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11810417.3A Withdrawn EP2596366A4 (de) 2010-07-21 2011-07-21 Kombinationstherapie mit mdm2 und efgr-hemmern

Country Status (3)

Country Link
EP (1) EP2596366A4 (de)
CA (1) CA2805658C (de)
WO (1) WO2012012653A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937178B2 (en) 2011-12-07 2018-04-10 Duke University Methods of identifying and using MDM2 inhibitors
WO2013192423A2 (en) 2012-06-20 2013-12-27 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
EP3388419A1 (de) * 2017-04-12 2018-10-17 Leadiant Biosciences SA Gli1-inhibitoren und deren verwendungen

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
US20100160313A1 (en) * 2008-10-22 2010-06-24 University Of Southern California Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
WO2011082175A2 (en) * 2009-12-31 2011-07-07 Zacharon Pharmaceuticals, Inc. Glycosaminoglycan inhibitors
WO2011085126A2 (en) * 2010-01-06 2011-07-14 Errico Joseph P Methods and compositions of targeted drug development

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107545A1 (en) * 2006-03-22 2007-09-27 Janssen Pharmaceutica N.V. Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
WO2009117484A2 (en) * 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
US20100160313A1 (en) * 2008-10-22 2010-06-24 University Of Southern California Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
WO2011082175A2 (en) * 2009-12-31 2011-07-07 Zacharon Pharmaceuticals, Inc. Glycosaminoglycan inhibitors
WO2011085126A2 (en) * 2010-01-06 2011-07-14 Errico Joseph P Methods and compositions of targeted drug development

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERKSON R G ET AL: "Pilot screening programme for small molecule activators of p53", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 115, no. 5, 10 July 2005 (2005-07-10), pages 701 - 710, XP008129829, ISSN: 0020-7136, [retrieved on 20050223], DOI: 10.1002/IJC.20968 *
DUTTA ET AL: "Cellular responses to EGFR inhibitors and their relevance to cancer therapy", CANCER LETTERS, NEW YORK, NY, US, vol. 254, no. 2, 8 September 2007 (2007-09-08), pages 165 - 177, XP022182281, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2007.02.006 *
IAN R HARDCASTLE: "Inhibitors of the MDM2-p53 interaction as anticancer drugs", DRUGS OF THE FUTURE 2007, PROUS SCIENCE, vol. 32, no. 10, 1 January 2007 (2007-01-01), pages 883 - 896, XP007919174, DOI: 10.1358/DOF.2007.032.10.1131965 *
See also references of WO2012012653A1 *

Also Published As

Publication number Publication date
CA2805658A1 (en) 2012-01-26
CA2805658C (en) 2016-12-13
EP2596366A1 (de) 2013-05-29
WO2012012653A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
GB201012175D0 (en) Procedure and mechanisms
IL249669B (en) Converted 5-fluoro-h1-pyrazolopyridines and their use
IL222481A0 (en) Combination therapy
IL221511A (en) Arilatriazolones associated with bis aryl and their use
EP2552323A4 (de) Kombinationstherapie
EP2542086A4 (de) Verbindungen und ihre therapeutische verwendung
ZA201303776B (en) Bromodomain inhibitors and uses thereof
EP2523630A4 (de) Systeme und verfahren für bariatrische therapie
ZA201208173B (en) Peptices and their use
EP2579865A4 (de) Kombinationstherapie mit lisdexamphetamin und guanfacin mit verlängerter freisetzung
AP2013006947A0 (en) Compounds and their use
IL212760A0 (en) Internal and external disc shunts alleviate back pain
HUE041512T2 (hu) Új kombináció és alkalmazás
GB201011411D0 (en) Therapeutic compounds and their use
EP2596366A4 (de) Kombinationstherapie mit mdm2 und efgr-hemmern
EP2624854A4 (de) Moesinmodulatoren und ihre verwendungen
EP2629766A4 (de) Kombinationstherapie
GB201102213D0 (en) Inventions and therapy
GB201102222D0 (en) Inventions and therapy
GB201102236D0 (en) Inventions and therapy
GB201102239D0 (en) Inventions and therapy
GB201102234D0 (en) Inventions and therapy
GB201102215D0 (en) Inventions and therapy
GB201102216D0 (en) Inventions and therapy
GB201102210D0 (en) Inventions and therapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ERRICO, JOSEPH P.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140319

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/517 20060101ALI20140313BHEP

Ipc: A61K 45/06 20060101ALI20140313BHEP

Ipc: A61K 31/4709 20060101AFI20140313BHEP

Ipc: A61P 35/00 20060101ALI20140313BHEP

17Q First examination report despatched

Effective date: 20150623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160105